Abstract Library

#2840 A Real-World Study of Patients with Carcinoid Syndrome at King’s College Hospital on Long-Term Telotristat Therapy

Introduction: Telotristat ethyl is a tryptophan hydroxylase inhibitor that has been shown to be effective against symptoms of carcinoid syndrome refractory to standard somatostatin analogue therapy by directly inhibiting serotonin production. While clinical trials have established short-term efficacy of the drug, we report an exploratory real-world study of 15 patients with metastatic neuroendocrine tumours on long-term Telotristat (median duration=8 months).

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Hota S, Cananea E, Martin W, Clement D, Solis B,

Keywords: Neuroendocrine tumours, carcinoid syndrome, telotristat ethyl,